Who Paid My Doc
Denise Rozzelle
Registered Nurse, Hospice Burlington, NJ Nurse Practitioner
NPI 1306203633 CMS profile 10758612
261 Connecticut Dr Ste 1, Burlington, NJ 08016
General payments
$19
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Denise Rozzelle of Burlington, NJ is reported in the CMS Open Payments database as having received $19 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $19 | 1 |
Beside peers
- Denise Rozzelle
- New Jersey median
- Middle half of New Jersey
- National median
In program year 2025, general payments to Denise Rozzelle were reported at $19. Among 31,834 New Jersey profiles paid that year, the median was $178 and the middle half received between $51 and $585.
Show as a table
| Year | Denise Rozzelle | New Jersey median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $150 | $44–$542 | $163 |
| 2020 | $0 | $110 | $33–$349 | $114 |
| 2021 | $0 | $125 | $36–$419 | $132 |
| 2022 | $0 | $142 | $42–$480 | $149 |
| 2023 | $0 | $156 | $48–$510 | $160 |
| 2024 | $0 | $167 | $50–$562 | $164 |
| 2025 | $19 | $178 | $51–$585 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 103 drugsPart D claims
4,179
Drug cost
$264,219
Branded share of claims
17.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 152 | $105,551 | |
| Ozempic Semaglutide | Brand | 20 | $20,656 | |
| Januvia Sitagliptin Phosphate | Brand | 24 | $20,155 | |
| Mounjaro Tirzepatide | Brand | 15 | $17,753 | |
| Jardiance Empagliflozin | Brand | 22 | $16,331 | |
| Dulera Mometasone/Formoterol | Brand | 12 | $4,225 | |
| Atorvastatin Calcium | Generic | 214 | $4,024 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 103 | $3,288 | |
| Levothyroxine Sodium | Generic | 201 | $2,838 | |
| Novolog Mix 70-30 Flexpen Insulin Aspart Prot/Insuln Asp | Brand | 12 | $2,390 |
The 10 drugs with the highest cost, of 103 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 30 billing codesPaid by Medicare
$265,646
Medicare patients
152
Services billed
2,850
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Depression | 63% | |
| Alzheimer's or dementia | 59% | |
| Arthritis | 54% | |
| Heart failure | 53% | |
| Diabetes | 40% | |
| Atrial fibrillation | 39% | |
| Ischemic heart disease | 34% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Registered Nurse, Hospice in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Registered Nurse, Hospice
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.